Columbia-Presbyterian prepares for permanent pump trials
This article was originally published in Clinica
The New York Columbia-Presbyterian Medical Center expects to start trials of permanent heart pump implants next year. Physicians at the centre pioneered the use of left ventricular assist devices (LVADs) in bridge-to-transplant patients. During a presentation at the American Heart Association annual meeting in Anaheim, California (November 13th-16th) Director of the circulatory assist program Dr Mehmet Oz said their success has encouraged them to set up a major trial in 1996.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.